Johnson & Johnson (NYSE:JNJ) Shares Bought by Lowe Brockenbrough & Co. Inc.

Lowe Brockenbrough & Co. Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,983 shares of the company’s stock after acquiring an additional 654 shares during the period. Johnson & Johnson makes up 1.5% of Lowe Brockenbrough & Co. Inc.’s portfolio, making the stock its 12th biggest position. Lowe Brockenbrough & Co. Inc.’s holdings in Johnson & Johnson were worth $19,669,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Formidable Asset Management LLC grew its holdings in Johnson & Johnson by 1.1% during the 1st quarter. Formidable Asset Management LLC now owns 9,270 shares of the company’s stock valued at $1,643,000 after purchasing an additional 98 shares in the last quarter. Isthmus Partners LLC grew its holdings in Johnson & Johnson by 3.6% during the 1st quarter. Isthmus Partners LLC now owns 65,180 shares of the company’s stock valued at $11,552,000 after purchasing an additional 2,293 shares in the last quarter. S.C. Financial Services Inc. grew its holdings in Johnson & Johnson by 2.9% during the 1st quarter. S.C. Financial Services Inc. now owns 10,513 shares of the company’s stock valued at $1,863,000 after purchasing an additional 301 shares in the last quarter. Wealth Dimensions Group Ltd. boosted its stake in Johnson & Johnson by 2.4% during the 1st quarter. Wealth Dimensions Group Ltd. now owns 16,331 shares of the company’s stock valued at $2,894,000 after acquiring an additional 378 shares during the last quarter. Finally, Titleist Asset Management LTD. boosted its stake in Johnson & Johnson by 15.8% during the 1st quarter. Titleist Asset Management LTD. now owns 22,457 shares of the company’s stock valued at $3,980,000 after acquiring an additional 3,057 shares during the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on JNJ shares. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating on the stock. Citigroup reduced their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Finally, The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Trading Down 0.4 %

Shares of NYSE:JNJ opened at $171.11 on Friday. The company has a market cap of $449.88 billion, a PE ratio of 24.91, a P/E/G ratio of 3.32 and a beta of 0.59. The company’s 50-day moving average price is $175.21 and its 200 day moving average price is $174.55. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. Johnson & Johnson’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $2.48 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.64%. Johnson & Johnson’s payout ratio is 65.79%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.